Why is Pfizer falling/rising?

As of 13-Aug, Pfizer Ltd. is experiencing a slight decline in its stock price, currently at 5,096.25, with a change of -0.4, representing a decrease of 0.01%. Today's price summary indicates that the stock has underperformed its sector by 1.5% and has reversed its trend after two consecutive days of gains. Over the past week, the stock has shown a modest increase of 0.86%, but it has underperformed over the longer term, with a 1-month decline of 7.27% and a year-to-date drop of 3.01%. Despite these challenges, the company benefits from a high dividend yield of 3.92% and has seen rising investor participation, with a 15.66% increase in delivery volume compared to the 5-day average. Additionally, Pfizer's strong management efficiency is reflected in its high return on equity (ROE) of 19.67% and a low debt-to-equity ratio, which may provide some stability amid the stock's recent fluctuations.
In the broader market context, Pfizer's performance contrasts with the benchmark Sensex, which has shown a slight decline of 0.01% over the past week. While Pfizer's short-term return is positive, the stock's longer-term performance has lagged behind the benchmark, with a 1-year decline of 11.97% compared to the Sensex's increase of 2.01%. This underperformance may reflect broader market trends or sector-specific challenges that are impacting investor sentiment. Overall, while Pfizer has some positive attributes, including strong management efficiency and a decent dividend yield, its recent price movement suggests a cautious outlook as it navigates both company-specific and market-wide pressures.